StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) bonds

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$72.76M
Long-term debt
Net debt
-$131.83M
After $204.60M of cash
Implied interest rate
12.39%
FY2025 interest ÷ average debt
Interest coverage
-7.9×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Notes and loans outstanding

As tagged in Tarsus Pharmaceuticals's 10-Q for the period ended Apr 30, 2024

Tarsus Pharmaceuticals's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySize
Pharmakon Credit Facility, Tranche One$25.00M
Pharmakon Credit Facility, Tranche Three$50.00M
Pharmakon Credit Facility, Tranche Two$50.00M

See a number that looks wrong?